Delivery Order SPE2DR25D3802-SPE2DR26F6VFE
- Not listed
- Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., received a delivery order award from the Defense Logistics Agency (DLA) on January 22, 2026, for Repatha 140 mg/ml SureClick auto-injectors valued at $20,648.93. This firm fixed-price delivery order is scheduled for completion by January 23, 2026, and represents a non-competitive, non-set-aside award. The products will be delivered to the company's headquarters location in Conshohocken, Pennsylvania. Repatha is a prescription medication...
- Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a firm fixed-price delivery order valued at $33,760.01 by the Defense Logistics Agency on January 27, 2026, for the supply of Repatha 140 mg/mL SureClick auto-injector medication. The delivery order, which carries an ultimate completion date of January 28, 2026, represents a non-competitive award issued without set-aside designation. Performance will be executed from the awardee's corporate office location in Conshohocken,...
- Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a delivery order valued at $44,909.34 by the Defense Logistics Agency on January 28, 2026, for the supply of Repatha 140 mg/mL SureClick auto-injectors. The contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. Performance will be executed from the prime contractor's location in Conshohocken, Pennsylvania, with an ultimate completion date...
- Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a delivery order valued at $7,258.92 by the Defense Logistics Agency (DLA) on January 13, 2026, for the supply of Repatha 140 mg/ml SureClick auto-injectors. The contract is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded transaction. Performance will be completed at the awardee's location in Conshohocken, Pennsylvania, with an ultimate completion date of January 14,...
- Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a $6,497.25 delivery order by the Defense Logistics Agency on January 21, 2026, for the supply of Repatha 140 mg/ml SureClick auto-injectors. The contract is non-competitive and structured as a firm fixed-price delivery order with an ultimate completion date of January 22, 2026. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is executed under Amerisourcebergen's...
- AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a delivery order valued at $31,317.04 by the Defense Logistics Agency (DLA) on January 23, 2026, for the supply of Repatha 140 mg/mL SureClick auto-injector pharmaceutical product. The contract is firm fixed-price with no set-aside designation and is scheduled for completion by January 26, 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a delivery order on January 28, 2026, by the Defense Logistics Agency for $11,137.26 to supply Repatha 140 mg/ml SureClick auto-injectors. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract under full and open competition. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of January 29,...
- Amerisourcebergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on January 23, 2026, for Repatha 140 mg/ml SureClick auto-injector medication. The competitively awarded, firm fixed-price delivery order has a ceiling value of $13,018.84 and an ultimate completion date of January 26, 2026. This award carries no set-aside designation, indicating the contract was competed on a full and open...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a $2,971.95 firm fixed-price delivery order from the Defense Logistics Agency on January 15, 2026, for Repatha 140 mg/ml SureClick auto-injectors. The award is unset-aside and competitively awarded, with an ultimate completion date of January 16, 2026. This delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s comprehensive Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $9,747.84 firm fixed-price delivery order to AmerisourceBergen Drug Corp (parent company Cencora, Inc.) on January 22, 2026, for the supply of Repatha 140 mg/ml SureClick auto-injectors. The order, with an ultimate completion date of January 23, 2026, was competitively awarded with no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under Cencora, Inc.'s...
- SPE2DR25D3802Indefinite Delivery Contract
- SPE2DR25D3802-SPE2DR26F6VFEDelivery Order
Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a delivery order valued at $12,091.56 by the Defense Logistics Agency (DLA) on January 27, 2026, for the supply of Repatha 140 mg/ml SureClick auto-injectors. This firm fixed-price delivery order, which is not set-aside and was competitively awarded, is scheduled for completion by January 28, 2026, with performance taking place at the awardee's corporate office in Conshohocken, Pennsylvania. Repatha is a prescription pharmaceutical used in the treatment of high cholesterol and represents part of the broader pharmaceutical supply requirements for military and federal healthcare systems. This delivery order is issued under Amerisourcebergen's parent company's larger Indefinite Delivery Contract with the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2031. This comprehensive IDC serves as the primary vehicle enabling Cencora, Inc. to supply an extensive portfolio of pharmaceutical products and medical supplies—including specialty medications, brand-name and generic drugs, vaccines, and medical devices—to support military healthcare programs globally. The contract supports critical federal medical procurement needs across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.1k | 1/26/26 |